Daiki Miki

4.8k total citations
99 papers, 2.3k citations indexed

About

Daiki Miki is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Daiki Miki has authored 99 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Hepatology, 68 papers in Epidemiology and 14 papers in Infectious Diseases. Recurrent topics in Daiki Miki's work include Hepatitis C virus research (60 papers), Liver Disease Diagnosis and Treatment (53 papers) and Hepatitis B Virus Studies (42 papers). Daiki Miki is often cited by papers focused on Hepatitis C virus research (60 papers), Liver Disease Diagnosis and Treatment (53 papers) and Hepatitis B Virus Studies (42 papers). Daiki Miki collaborates with scholars based in Japan, United States and Italy. Daiki Miki's co-authors include Kazuaki Chayama, C. Nelson Hayes, Hidenori Ochi, Michio Imamura, Hiromi Abe, Masataka Tsuge, Nobuhiko Hiraga, Hiroshi Aikata, Shoichi Takahashi and Michiaki Kubo and has published in prestigious journals such as Nature Genetics, PLoS ONE and Hepatology.

In The Last Decade

Daiki Miki

96 papers receiving 2.3k citations

Peers

Daiki Miki
Elisabetta Cariani Italy
Shi‐Ming Lin Taiwan
Magdalena Filipowicz Sinnreich Switzerland
S. Koi Japan
Hey‐Chi Hsu Taiwan
Xiangjun Zhai China
Sophie Krieger France
Karine Poussin France
R. Bart Takkenberg Netherlands
Hideharu Harada Japan
Elisabetta Cariani Italy
Daiki Miki
Citations per year, relative to Daiki Miki Daiki Miki (= 1×) peers Elisabetta Cariani

Countries citing papers authored by Daiki Miki

Since Specialization
Citations

This map shows the geographic impact of Daiki Miki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daiki Miki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daiki Miki more than expected).

Fields of papers citing papers by Daiki Miki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daiki Miki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daiki Miki. The network helps show where Daiki Miki may publish in the future.

Co-authorship network of co-authors of Daiki Miki

This figure shows the co-authorship network connecting the top 25 collaborators of Daiki Miki. A scholar is included among the top collaborators of Daiki Miki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daiki Miki. Daiki Miki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fujino, Hatsue, Masataka Tsuge, Yasutoshi Fujii, et al.. (2025). Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B. Journal of Gastroenterology. 60(4). 469–478.
2.
Ono, Atsushi, C. Nelson Hayes, Ryoichi Miura, et al.. (2025). Multiomics Analysis of Liver Molecular Dysregulation Leading to Nonviral-Related Hepatocellular Carcinoma Development. Journal of Proteome Research. 24(3). 1102–1117.
3.
4.
5.
Fujii, Yasutoshi, Tomokazu Kawaoka, Ryoichi Miura, et al.. (2024). First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Oncology. 103(8). 742–747. 3 indexed citations
6.
Bao, Hongmei, Masataka Tsuge, Takuro Uchida, et al.. (2024). Alteration of Gene Expression After Entecavir and Pegylated Interferon Therapy in HBV-Infected Chimeric Mouse Liver. Viruses. 16(11). 1743–1743. 1 indexed citations
7.
Fujii, Yasutoshi, Atsushi Ono, C. Nelson Hayes, et al.. (2024). Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma. Cancers. 16(7). 1328–1328. 3 indexed citations
8.
Fujino, Hatsue, Yasutoshi Fujii, Shinsuke Uchikawa, et al.. (2024). Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs. Hepatology Research. 54(11). 981–992. 1 indexed citations
9.
Uchikawa, Shinsuke, Tomokazu Kawaoka, Ryoichi Miura, et al.. (2024). Time trend of outcomes according to systemic therapy for patients with unresectable hepatocellular carcinoma: A single‐institution study. Hepatology Research. 55(2). 283–290. 1 indexed citations
10.
Miki, Daiki, C. Nelson Hayes, Yuji Teraoka, et al.. (2024). Multi-omics analysis of a fatty liver model using human hepatocyte chimeric mice. Scientific Reports. 14(1). 3362–3362. 5 indexed citations
11.
Miura, Ryoichi, Atsushi Ono, Yasutoshi Fujii, et al.. (2024). Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. Journal of Gastroenterology. 60(3). 328–339. 3 indexed citations
12.
Miura, Ryoichi, Atsushi Ono, Yasutoshi Fujii, et al.. (2024). Real-world efficacy and safety of durvalumab–tremelimumab as second-line systemic therapy after atezolizumab–bevacizumab in unresectable hepatocellular carcinoma. Medicine. 103(34). e39289–e39289. 5 indexed citations
13.
Uchida, Takuro, Masataka Tsuge, Eisuke Murakami, et al.. (2023). Acute liver injury in a non-alcoholic fatty liver disease patient with chloroform exposure: a case report. Clinical Journal of Gastroenterology. 16(2). 250–253. 2 indexed citations
14.
Ono, Atsushi, et al.. (2022). Low-Dose Alcohol-Induced Inhibition of Mouse Orthotopically Transplanted Tumors Is Associated with T-Cell Response. Pathobiology. 90(1). 22–30. 1 indexed citations
15.
Fujii, Yasutoshi, Atsushi Ono, C. Nelson Hayes, et al.. (2021). Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib. Journal of Experimental & Clinical Cancer Research. 40(1). 215–215. 32 indexed citations
16.
Tada, Toshifumi, Hidenori Toyoda, Takashi Kumada, et al.. (2020). Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis. Journal of Viral Hepatitis. 28(3). 538–547. 2 indexed citations
17.
Fujino, Hatsue, Mio Tanaka, Michio Imamura, et al.. (2019). Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis. BMC Gastroenterology. 19(1). 169–169. 15 indexed citations
18.
Tanimine, Naoki, Yuka Tanaka, Tsuyoshi Kobayashi, et al.. (2014). Quantitative Effect of Natural Killer–Cell Licensing on Hepatocellular Carcinoma Recurrence after Curative Hepatectomy. Cancer Immunology Research. 2(12). 1142–1147. 18 indexed citations
19.
Chayama, Kazuaki, C. Nelson Hayes, Hiromi Abe, et al.. (2011). IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C. The Journal of Infectious Diseases. 204(1). 84–93. 96 indexed citations
20.
Miki, Daiki, Hidenori Ochi, C. Nelson Hayes, et al.. (2011). Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nature Genetics. 43(8). 797–800. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elisabetta Cariani Breakdown of academic impact, for papers by Shi‐Ming Lin Breakdown of academic impact, for papers by Magdalena Filipowicz Sinnreich Breakdown of academic impact, for papers by S. Koi Breakdown of academic impact, for papers by Hey‐Chi Hsu Breakdown of academic impact, for papers by Xiangjun Zhai Breakdown of academic impact, for papers by Sophie Krieger Breakdown of academic impact, for papers by Karine Poussin Breakdown of academic impact, for papers by R. Bart Takkenberg Breakdown of academic impact, for papers by Hideharu Harada
Rankless by CCL
2026